Granules Pharmaceuticals, Inc. Clears US FDA Audit

Granules India Limited, announced that Granules Pharmaceuticals, Inc. (GPI), a wholly-owned foreign subsidiary of the company, located in Chantilly, Virginia, USA received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA).

The GPI facility was inspected by the US FDA from 24th to 28th January 2022 for two of its product applications filed. There were three minor observations during the inspection and GPI had addressed the observations in the stipulated time period.

Commenting on the audit Ms. Priyanka Chigurupati, Executive Director, GPI, said "We are glad to have completed yet another audit after successfully addressing minor observations. This is the sixth successful US FDA audit for this facility."

Shares of Granules India Limited was last trading in BSE at Rs. 302.80 as compared to the previous close of Rs. 308.40. The total number of shares traded during the day was 134686 in over 3041 trades.

The stock hit an intraday high of Rs. 311.50 and intraday low of 300.75. The net turnover during the day was Rs. 40926195.00.

Source : Equity Bulls

Keywords

GranulesIndia INE101D01020 GranulesPharmaceuticals EIR USFDA